Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

ThunderCoopersmith Dec. 26 at 1:19 AM

$LXRX welp, here we go again smh

1 · Reply

macrossluvsrobotech Dec. 26 at 12:55 AM

$LXRX I expanded on this =

0 · Reply

SniperPro Dec. 26 at 12:29 AM

$LXRX Merry Christmas, ST family.... Remember, today is about our Lord Jesus and our dear families... Be the best version of yourself... We take nothing with us into the next life except good memories... May the Lord bless our souls and keep the light in our hearts... Money comes and goes, but good hearts are forever. I Fucking Love You All. No exceptions, all are welcome to Heaven! Peace be upon your hearts!!! Grinchy out. 🌲🔥💐❄️☃️✨🎉🎊❤️🎡🎈🎁🎀🍬🍰🧁🍭

0 · Reply

Buttermaker007 Dec. 25 at 12:39 PM

$LXRX to all of you! Merry Christmas everybody and a happy new year ! 2026 will be epic

0 · Reply

Thekareemofthecrop Dec. 24 at 9:30 PM

$LXRX sharing my DD on LXRX. 13,000 views! https://www.reddit.com/r/LXRXstock/s/bipxcVRYoG

3 · Reply

Jas7235355 Dec. 24 at 8:26 PM

$LXRX thought Exton said there would be news in 4Q? Only got a hand full of days left????

3 · Reply

Dooright Dec. 24 at 6:31 PM

$LXRX Merry Christmas and happy, healthy and safe holidays to everyone. See y’all on Friday! Doc C. 🤓

0 · Reply

macrossluvsrobotech Dec. 24 at 6:05 PM

$LXRX Exciting times. Happy Holidays to everyone.

0 · Reply

beezee8 Dec. 24 at 4:11 PM

$LXRX Well friends, another year is coming to a close and we're up 60% in 2025, outperforming the SPY and QQQ by 4 X. At the start of the year I would have certainly taken it. We know what we own, and I'm sure all the foundations that have been built will lead to even bigger gains in 2026. In the meantime hope you all have a great Christmas and the rest of the holiday season

1 · Reply

Dooright Dec. 24 at 3:11 PM

$LXRX Well, so far, a big lump of coal for us. Maybe Mikey Exton is an agnostic and doesn’t believe in giving presents for Christmas. 😆 In that case, I would take a New Year’s gift or maybe even a Valentine gift? 😂 Regardless, none of us are getting any younger. Doc C. 🤓

1 · Reply

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 5, 2025, 8:30 AM EST - 20 days ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Dec 3, 2025, 10:30 AM EST - 22 days ago

Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well

Nov 25, 2025, 8:30 AM EST - 4 weeks ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 19, 2025, 3:53 PM EST - 5 weeks ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 15, 2025, 6:46 AM EST - 5 weeks ago

Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win

Nov 11, 2025, 8:30 AM EST - 6 weeks ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Nov 8, 2025, 2:30 PM EST - 6 weeks ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 6, 2025, 2:16 PM EST - 7 weeks ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 7 weeks ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 4, 2025, 8:30 AM EST - 7 weeks ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Oct 30, 2025, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 14, 2025, 8:00 AM EDT - 2 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 2 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 3 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 3 months ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 8:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 4 months ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 7:36 PM EDT - 4 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 8:30 AM EDT - 4 months ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 4 months ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 4 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 12:39 PM EDT - 5 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:30 AM EDT - 5 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 5 months ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 5 months ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 5 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 23, 2025, 8:00 AM EDT - 6 months ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 6 months ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

May 29, 2025, 8:00 AM EDT - 7 months ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 7 months ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 9:47 PM EDT - 8 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:00 PM EDT - 8 months ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 8 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 8 months ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 25, 2025, 9:00 AM EDT - 8 months ago

Top 2 Health Care Stocks That May Crash This Month

Apr 2, 2025, 8:00 AM EDT - 9 months ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 10:09 AM EDT - 9 months ago

Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal

NVO

Mar 28, 2025, 9:02 AM EDT - 9 months ago

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

NVO

Mar 28, 2025, 7:30 AM EDT - 9 months ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Mar 7, 2025, 8:30 AM EST - 10 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Mar 6, 2025, 10:52 PM EST - 10 months ago

Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:00 PM EST - 10 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 4:15 PM EST - 10 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Mar 3, 2025, 7:00 AM EST - 10 months ago

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Mar 2, 2025, 4:13 PM EST - 10 months ago

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Feb 18, 2025, 8:00 AM EST - 11 months ago

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Jan 21, 2025, 8:00 AM EST - 1 year ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Jan 2, 2025, 8:00 AM EST - 1 year ago

Lexicon Appoints Scott Coiante as Chief Financial Officer

ThunderCoopersmith Dec. 26 at 1:19 AM

$LXRX welp, here we go again smh

1 · Reply

macrossluvsrobotech Dec. 26 at 12:55 AM

$LXRX I expanded on this =

0 · Reply

SniperPro Dec. 26 at 12:29 AM

0 · Reply

Buttermaker007 Dec. 25 at 12:39 PM

$LXRX to all of you! Merry Christmas everybody and a happy new year ! 2026 will be epic

0 · Reply

Thekareemofthecrop Dec. 24 at 9:30 PM

$LXRX sharing my DD on LXRX. 13,000 views! https://www.reddit.com/r/LXRXstock/s/bipxcVRYoG

3 · Reply

Jas7235355 Dec. 24 at 8:26 PM

$LXRX thought Exton said there would be news in 4Q? Only got a hand full of days left????

3 · Reply

Dooright Dec. 24 at 6:31 PM

$LXRX Merry Christmas and happy, healthy and safe holidays to everyone. See y’all on Friday! Doc C. 🤓

0 · Reply

macrossluvsrobotech Dec. 24 at 6:05 PM

$LXRX Exciting times. Happy Holidays to everyone.

0 · Reply

beezee8 Dec. 24 at 4:11 PM

1 · Reply

Dooright Dec. 24 at 3:11 PM

1 · Reply

Beebomb Dec. 24 at 12:48 PM

$LXRX If you have any interest in understanding Novo's business, check out the last article at WIRED Daily <[email protected]>.

0 · Reply

kampochea Dec. 24 at 9:00 AM

$LXRX as short message concerning approval Wegovy oral / 1. Biological Plausibility (⭐️⭐️⭐️⭐️⭐️ very high) Why this matters: Combination therapies often fail because their mechanisms overlap or counteract each other. That is not the case here. GLP-1 (Wegovy / oral semaglutide) Reduces appetite (central nervous system) Slows gastric emptying Limits caloric intake LX9851 (ACSL5 inhibitor) Acts peripherally (gut, liver, adipose tissue) Alters fatty acid metabolism Promotes fat oxidation rather than storage Has no effect on appetite 👉 Conclusion: The mechanisms are orthogonal → synergy is likely, antagonism is highly unlikely. 📊 Probability score: ~85–90%

1 · Reply

gucag006 Dec. 24 at 4:50 AM

$LXRX The correlation between LX9851 and GLP-1 drugs is very low. The strongest connection between the two is Novo Nordisk. The common side effects of GKO-1 drugs are: Very Common (Often Mild to Moderate): Nauea & Vomiting: Extremely common, often reducing as treatment continues. Diarrhea & Constipation: Both can occur, with diarrhea sometimes leading to dehydration. Loss of Appetite & Decreased Hunger: A desired effect, but can contribute to fatigue. Abdominal Pain & Bloating: Digestive discomfort. Fatigue & Dizziness: As your body adapts. Less Common but Serious: Pancreatitis: Inflammation of the pancreas, signaled by severe abdominal pain. Gallbladder Disease & Gallstones: Rapid weight loss increases this risk, causing pain. Kidney Problems: Dehydration from vomiting/diarrhea can strain kidneys. Allergic Reactions: Serious reactions are possible. LX9851 only went thru animal trial, and lis safe profile is yet to be determined.

0 · Reply

hykchiu Dec. 24 at 3:18 AM

$LXRX just read news about abvx, so lexi 10x is possible

0 · Reply

Rafrica Dec. 23 at 10:52 PM

$LXRX https://finance.yahoo.com/news/lexicon-pharmaceuticals-inc-nasdaq-lxrx-100017573.html

0 · Reply

Bearfaith Dec. 23 at 8:21 PM

$LXRX $NVO ASBP is developing wegovy sublingual nano technology - bypasses gut and liver….

1 · Reply

Buttermaker007 Dec. 23 at 8:04 PM

$LXRX bullish

0 · Reply

beezee8 Dec. 23 at 5:22 PM

$LXRX Following the NVO news I'm sure that IND submission is being rushed as we speak

1 · Reply

SniperPro Dec. 23 at 5:18 PM

$NVO 🚨🚨 WHAT ARE YOU WAITING FOR ???? 🚨🚨 💹 💹 💹 $LXRX FILE LX9851 IND... NOW!!! 💹 💹 💹 " Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for completing agreed upon Investigational New Drug (IND) application-enabling activities for LX9851. Novo Nordisk will be responsible for filing the IND, all further development, manufacturing and commercialization of LX9851."

0 · Reply

SniperPro Dec. 23 at 4:52 PM

$LXRX Awesome post Iman, watch it or listen, very informative... BOOM

0 · Reply

HammaSalammin Dec. 23 at 4:52 PM

$LXRX Behold! The PhrMA that gets an approval, has another potentially revolutionary drug that had fast track, that trades a 1 lonely dollar! Theze executives cant make a deal!

0 · Reply

HammaSalammin Dec. 23 at 4:49 PM

$LXRX just checking in! Look! Nothing has changed! Still a shit-burger!

0 · Reply

Market Cap	446.98M
Revenue (ttm)	31.08M
Net Income (ttm)	-200.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-644.79%
Debt to Equity Ratio	0.47

Volume	748,000
Avg Vol	1,898,234
Day's Range	N/A - N/A
Shares Out	363.40M
Stochastic %K	49%
Beta	0.96
Analysts	Sell
Price Target	$2.88